<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cytomx Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc</link>
<description>Latest news and press releases for Cytomx Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cytomx-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355a8778dffbe2df0eb840.webp</url>
<title>Cytomx Therapeutics Inc</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc</link>
</image>
<item>
<title>CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-pricing-of-dollar250-million-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-pricing-of-dollar250-million-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Mon, 16 Mar 2026 20:04:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock</description>
</item>
<item>
<title>CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal</description>
</item>
<item>
<title>CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-16-2026-18</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-16-2026-18</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics to Present at Upcoming February Conferences</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-february-130000221</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-february-130000221</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK A</description>
</item>
<item>
<title>Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cardiff-oncology-announces-executive-leadership-changes-as-it-transitions-to-late-stage-clinical-development</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cardiff-oncology-announces-executive-leadership-changes-as-it-transitions-to-late-stage-clinical-development</guid>
<pubDate>Tue, 27 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned biotech executiv</description>
</item>
<item>
<title>Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/wareham-development-leases-full-floor-at-emerystation-research-campus-to-cytomx-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/wareham-development-leases-full-floor-at-emerystation-research-campus-to-cytomx-therapeutics</guid>
<pubDate>Wed, 21 Jan 2026 20:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., January 21, 2026--Wareham Development today confirmed a full floor lease has been signed with CytomX Therapeutics at 5959 Horton Street (EmeryStation West).</description>
</item>
<item>
<title>CytomX Therapeutics Announces Business Update and Company Milestones for 2026</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-business-update-and-company-milestones-2026-2026-01-08</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-business-update-and-company-milestones-2026-2026-01-08</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination</description>
</item>
<item>
<title>CytomX Therapeutics to Present at Upcoming December Investor Conferences</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-december-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-december-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics to Present at the Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-jefferies-london-healthcare-conference-2025-11-13</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-jefferies-london-healthcare-conference-2025-11-13</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1</description>
</item>
<item>
<title>CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-cx-801-phase-1-monotherapy-biomarker-data-society</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-cx-801-phase-1-monotherapy-biomarker-data-society</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - -</description>
</item>
<item>
<title>CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-report-third-quarter-2025-financial-results-november-6-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-report-third-quarter-2025-financial-results-november-6-2025-2025</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-appoints-rachael-lester-chief-business-officer-2025-10-20</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-appoints-rachael-lester-chief-business-officer-2025-10-20</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Leadership team addition to drive strategic long-term value creation and partnering strategy SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>CytomX Therapeutics to Present at Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-september-investor-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-upcoming-september-investor-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-provides-update-cx-2051-phase-1-study-2025-08-13</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-provides-update-cx-2051-phase-1-study-2025-08-13</guid>
<pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
<description>- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 -</description>
</item>
<item>
<title>CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced</description>
</item>
<item>
<title>CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-report-second-quarter-2025-financial-results-august-7-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-report-second-quarter-2025-financial-results-august-7-2025-2025</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-jefferies-global-healthcare-conference-2025-05-29</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-present-jefferies-global-healthcare-conference-2025-05-29</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
<item>
<title>CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma</title>
<link>https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-first-patient-dosed-combination-arm-phase-1-study-cx</link>
<guid isPermaLink="true">https://6ix.com/company/cytomx-therapeutics-inc/news/cytomx-therapeutics-announces-first-patient-dosed-combination-arm-phase-1-study-cx</guid>
<pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally</description>
</item>
</channel>
</rss>